急性缺血性脑中风治疗市场规模、份额、成长分析（按诊断、药物类别和地区）- 产业预测（2025 年至 2032 年）

预计 2023 年全球急性缺血性脑中风治疗市场价值将达到 84 亿美元，并从 2024 年的 91.3 亿美元增长到 2032 年的 178 亿美元，预测期内（2025-2032 年）的复合年增长率为 8.7%。

由于脑血管疾病的盛行率不断上升，以及先进溶栓药物和机械血栓切除术的日益普及，全球急性缺血性脑中风治疗市场正在经历显着增长。推动这一市场发展的关键因素是高血压、糖尿病和心房颤动等生活方式相关风​​险因素的发病率不断上升，这些因素会增加中风风险，并加剧了及时干预的需求。然而，高昂的治疗费用和不足的诊断基础设施（尤其是在医疗资源匮乏的地区）阻碍了中风的可及性，并且治疗窗口狭窄。北美凭藉其强大的认知度、健全的医疗保健系统和优惠的报销政策，占据了市场主导地位。同时，对卒中治疗和人工智慧诊断的持续投资预计将进一步推动该领域的成长。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 顾客购买行为分析

急性缺血性脑中风治疗市场规模（按诊断和复合年增长率）（2025-2032）

• 市场概览
• CT
• MRI
• 颈动脉超音波
• 脑血管血管造影术

急性缺血性脑中风治疗市场规模（依药物类别及复合年增长率）（2025-2032）

• 市场概览
• 组织胞浆素原原激活剂
• 抗凝血剂
• 抗血小板药物
• 抗高血压药物

急性缺血性脑中风治疗市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 按部门分類的公司份额分析
  • 收益同比对比（2022-2024 年）

主要企业简介

• Amgen Inc.（United States）
• Pfizer Inc.（United States）
• Sanofi SA（France）
• Novartis International AG（Switzerland）
• Johnson & Johnson（United States）
• Merck & Co., Inc.（United States）
• GlaxoSmithKline plc（United Kingdom）
• AbbVie Inc.（United States）
• Bayer AG（Germany）
• Bristol Myers Squibb（United States）
• AstraZeneca plc（United Kingdom）
• Eli Lilly and Company（United States）
• Takeda Pharmaceutical Company Limited（Japan）

结论和建议

Global Acute Ischemic Stroke Therapeutics Market size was valued at USD 8.4 billion in 2023 and is poised to grow from USD 9.13 billion in 2024 to USD 17.8 billion by 2032, growing at a CAGR of 8.7% during the forecast period (2025-2032).

The global market for acute ischemic stroke therapeutics is witnessing significant growth, driven by the increasing prevalence of cerebrovascular diseases and the heightened adoption of advanced thrombolytics and mechanical thrombectomy techniques. A major factor fueling this market is the rising incidence of lifestyle-related risk factors such as hypertension, diabetes, and atrial fibrillation, which elevate stroke risk and heighten the necessity for timely interventions. However, challenges persist due to the narrow therapeutic window that limits treatment eligibility, especially in underserved areas, alongside high treatment costs and inadequate diagnostic infrastructure that hinder accessibility. North America dominates the market, supported by strong awareness, robust healthcare systems, and favorable reimbursement practices, while ongoing investments in stroke care and AI diagnostics promise to further propel growth in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Acute Ischemic Stroke Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Acute Ischemic Stroke Therapeutics Market Segments Analysis

Global Acute Ischemic Stroke Therapeutics Market is segmented by Diagnosis, Drug Class and region. Based on Diagnosis, the market is segmented into CT, MRI, Carotid Ultrasound and Cerebral Angiography. Based on Drug Class, the market is segmented into Tissue Plasminogen Activator, Anticoagulant, Antiplatelet and Antihypertensive. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Acute Ischemic Stroke Therapeutics Market

The global acute ischemic stroke therapeutics market is significantly influenced by the rising prevalence of stroke, especially within aging demographics. As strokes represent a leading cause of disability and mortality worldwide, the demand for effective treatments has surged. The increasing life expectancy across various populations has heightened the vulnerability to strokes, resulting in a greater need for advanced therapeutics such as thrombolytics, neuroprotective agents, and mechanical thrombectomy techniques. This growing awareness and need for timely and effective intervention in stroke management continue to propel the development and availability of innovative therapeutic solutions in the market.

Restraints in the Global Acute Ischemic Stroke Therapeutics Market

A significant challenge in addressing ischemic stroke lies in the limited treatment window, usually within a few hours for effective thrombolysis. Delays in recognizing symptoms and reaching medical facilities often result in missed chances for treatment. This issue is further compounded in many low- and middle-income areas, where limited access to advanced imaging technologies and a shortage of trained stroke specialists can lead to delays in diagnosis and intervention. Such barriers ultimately restrict the availability and implementation of therapeutic options, hindering the overall management of acute ischemic stroke in affected populations.

Market Trends of the Global Acute Ischemic Stroke Therapeutics Market

The Global Acute Ischemic Stroke Therapeutics market is witnessing a transformative trend driven by the integration of personalized medicine and Artificial Intelligence (AI). By leveraging AI to accurately assess clot locations, predict treatment responses, and inform therapeutic decisions, healthcare providers are enhancing the efficacy of acute stroke interventions. Coupled with advancements in genomics and biomarkers, this trend is fostering more targeted treatment approaches, resulting in optimized patient outcomes. Hospitals that implement AI-assisted stroke triage systems are demonstrating significant improvements in crucial metrics, such as reduced door-to-needle times, which is further propelling interest and investment in innovative stroke care solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Acute Ischemic Stroke Therapeutics Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• CT
• MRI
• Carotid Ultrasound
• Cerebral Angiography

Global Acute Ischemic Stroke Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Tissue Plasminogen Activator
• Anticoagulant
• Antiplatelet
• Antihypertensive

Global Acute Ischemic Stroke Therapeutics Market Size & CAGR (2025-2032)

• North America (Diagnosis, Drug Class)
  • US
  • Canada
• Europe (Diagnosis, Drug Class)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Drug Class)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Drug Class)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Drug Class)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations